Pennsylvania-gebaseerde JBS Science het vandag gesê dat dit die $ 3 miljoen Bridge Award vir Small Business Innovation Research IIB van die National Cancer Institute ontvang het. Die maatskappy het die eerste vloeibare biopsieproduk ontwikkel, wat urine-DNS-sifting vir vroeë lewerselkanker (HCC) is.
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of lewerkanker. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating tumor DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
JBS het gesê hy het saamgewerk met James Hamilton van Johns Hopkins Universiteit Mediese Sentrum en Hie-Won Hann van Thomas Universiteit Hospitaal om die ontwikkeling van lewerkanker urinetoets te bevorder.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
